351 related articles for article (PubMed ID: 30714987)
21. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
22. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
[TBL] [Abstract][Full Text] [Related]
23. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL; Disis ML
Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
[TBL] [Abstract][Full Text] [Related]
24. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
Hernández J; Lee PP; Davis MM; Sherman LA
J Immunol; 2000 Jan; 164(2):596-602. PubMed ID: 10623800
[TBL] [Abstract][Full Text] [Related]
25. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
26. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
Kuball J; Schmitz FW; Voss RH; Ferreira EA; Engel R; Guillaume P; Strand S; Romero P; Huber C; Sherman LA; Theobald M
Immunity; 2005 Jan; 22(1):117-29. PubMed ID: 15664164
[TBL] [Abstract][Full Text] [Related]
27. Systems-guided forward genetic screen reveals a critical role of the replication stress response protein ETAA1 in T cell clonal expansion.
Miosge LA; Sontani Y; Chuah A; Horikawa K; Russell TA; Mei Y; Wagle MV; Howard DR; Enders A; Tscharke DC; Goodnow CC; Parish IA
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5216-E5225. PubMed ID: 28607084
[TBL] [Abstract][Full Text] [Related]
28. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
29. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
Lo W; Parkhurst M; Robbins PF; Tran E; Lu YC; Jia L; Gartner JJ; Pasetto A; Deniger D; Malekzadeh P; Shelton TE; Prickett T; Ray S; Kivitz S; Paria BC; Kriley I; Schrump DS; Rosenberg SA
Cancer Immunol Res; 2019 Apr; 7(4):534-543. PubMed ID: 30709841
[TBL] [Abstract][Full Text] [Related]
30. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
[TBL] [Abstract][Full Text] [Related]
31. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K
Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478
[TBL] [Abstract][Full Text] [Related]
32. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
[TBL] [Abstract][Full Text] [Related]
33. Epitope identification for p53R273C mutant.
Zhang J; Liu M; Chen Y; Zhou Z; Wang P; Yu Y; Jiao S
Immun Inflamm Dis; 2023 Jan; 11(1):e752. PubMed ID: 36705409
[TBL] [Abstract][Full Text] [Related]
34. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes.
Dangles V; Halberstam I; Scardino A; Choppin J; Wertheimer M; Richon S; Quelvennec E; Moirand R; Guillet JG; Kosmatopoulos K; Bellet D; Zeliszewski D
Cancer Immunol Immunother; 2002 Feb; 50(12):673-81. PubMed ID: 11862419
[TBL] [Abstract][Full Text] [Related]
36. Role of the MHC restriction during maturation of antigen-specific human T cells in the thymus.
Hesnard L; Legoux F; Gautreau L; Moyon M; Baron O; Devilder MC; Bonneville M; Saulquin X
Eur J Immunol; 2016 Mar; 46(3):560-9. PubMed ID: 26635029
[TBL] [Abstract][Full Text] [Related]
37. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
39. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
40. A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors.
Foster AE; Bradstock KF; Sili U; Marangolo M; Rooney CM; Gottlieb DJ
Biol Blood Marrow Transplant; 2004 Nov; 10(11):761-71. PubMed ID: 15505607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
